Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Status Active, not recruiting

Clinical Trial Summary

This is a single-center, retrospective clinical study to evaluate the efficacy and safety of tislelizumab combined with first-line chemotherapy in the treatment of HER2-negative advanced gastric cancer.

Clinical Trial Description

This study aims to include 60 HER-2 negative advanced gastric cancer patients who received first-line treatment with tislelizumab combined with chemotherapy in our hospital from November 1, 2020 to November 1, 2021. Clinicopathological data, blood tests and imaging data of the patients were collected. The primary endpoints evaluated were PFS and OS, and the secondary endpoints were ORR and safety. At the same time, ctDNA and peripheral cytokine status of patients as well as second-generation sequencing of tumor tissues at baseline were collected for the exploration of therapeutic efficacy related biomarkers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06034964
Study type	Observational
Source	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact
Status	Active, not recruiting
Phase
Start date	November 1, 2020
Completion date	November 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03652727` - FX vs. ECG Guidance for PICC Insertion	N/A
Not yet recruiting	`NCT05856656` - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer	N/A
Active, not recruiting	`NCT02959541` - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer	N/A
Completed	`NCT00757094` - Safety and Feasibility of Fasting While Receiving Chemotherapy	N/A
Recruiting	`NCT00797238` - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	N/A
Not yet recruiting	`NCT05927857` - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .	Phase 1/Phase 2
Recruiting	`NCT04453826` - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Phase 3
Completed	`NCT04466332` - Comparison of Two ECG Guided PICC Insertion Techniques	N/A
Not yet recruiting	`NCT04055038` - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	Phase 2/Phase 3
Recruiting	`NCT03701607` - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting	`NCT04024241` - Medium Dose of Cytarabine and Mitoxantrone
Recruiting	`NCT06208436` - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting	`NCT05306301` - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients	Phase 2
Active, not recruiting	`NCT02304640` - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed	`NCT02298972` - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer	N/A
Terminated	`NCT01249001` - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents	Phase 2
Recruiting	`NCT03089892` - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy	N/A
Recruiting	`NCT05125055` - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC	Phase 2/Phase 3
Recruiting	`NCT04472403` - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated	`NCT02982694` - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer	Phase 2